

**PVR**

Refer to important disclosures at the end of this report

# Weak Bollywood performance a drag

<b>CMP</b>	<b>Target Price</b>
<b>Rs 1,689</b> as of (October 17, 2022)	<b>Rs 2,340 (■)</b> 12 months
<b>Rating</b>	<b>Upside</b>
<b>BUY (■)</b>	<b>38.6 %</b>

PVR's operating performance reflected the poor box-office collections in Q2FY23. Footfalls declined 28% QoQ, resulting in a 30% decline in revenue. ATP and SPH also declined sequentially from the all-time high in Q1FY23, attributable to weaker movie performance and special promotional offers. Ad revenue held up better, though it continues to be below pre-Covid levels. The company opened only 14 screens in H1FY23, even as Management stays confident of meeting its target of 110-125 screen-additions for FY23. In our view, content acceptance remains the primary factor for PVR's success. Despite the weak performance in the quarter, we maintain our FY24/25 estimates, in the hope of a Bollywood content-reversal. However, if this weakness persists, the risk of an earnings cut and a de-rating looms large. We maintain BUY with an unchanged TP of Rs2,340/share (Sep-24E pro forma EBITDA).

**Results Summary:** Revenue declined 30% QoQ to Rs6.9bn in Q2FY23, largely attributable to the unrelenting weak Bollywood performance. While regional movies saw robust collections in the quarter, mega blockbusters – which had propelled box-office collections in Q1FY23 – were missing. In Q2FY23, Hollywood saw one of its weakest performances in the last two decades, due to lack of movie releases. Consequently, NBOC declined 38% QoQ to Rs3.3bn. Lower number of blockbuster movies also resulted in moderation of both, ATP and SPH, in the quarter. ATP fell to Rs224 (from Rs250 in Q1FY23) and SPH fell to Rs129 (from Rs134 in Q1FY23) – Both were also affected by the special initiatives aimed at driving-up footfalls. Overall, F&B sales also declined, by 29% QoQ to Rs2.3bn. Advertising revenue fall of 9% QoQ was not as sharp. EBITDA fell 55% QoQ due to flow-through of lower revenue, but still outclassed our estimates, as film exhibition costs and employee expenses were 8% and 12% (respectively) lower than our estimates. PVR reported net loss of Rs712mn vs our estimate of a Rs804mn loss. Net debt at end-Q2 was Rs11bn vs. Rs8.4bn at end-Q1FY23.

**Earnings Call KTAs:** 1) **Ticket Pricing:** Company is malleable to explore a different pricing mechanism. Pricing is not the sole factor for driving footfalls, with content being the single most-important factor. Q3 ATP should be close to that seen in Q1FY23; SPH should be Rs135-140, going ahead. 2) **Footfalls:** Lower footfalls are not a result of lack of appetite; decline in the quarter was only due to unfavorable content. While PVR's mainstay is feature films, alternative content being screened is also part of its strategy, which is key to attract audiences to theaters. 3) **Regional Cinema:** Seeing support from the regional industry for wider audiences, by dubbing in more languages. Footfalls in South India remain substantially strong. 4) **Ad revenue:** Recovery is taking a bit longer than expected; PVR saw 62% recovery in current quarter compared with 2019; should recover to 70-72% of the 2019 levels by Q4FY23. 5) **Screen Guidance:** PVR is fairly confident about meeting screen-addition guidance of 110-125 in FY23, despite opening only 14 screens in H1FY23. 6) **Merger:** Both PVR and Inox have received shareholder approval. The final leg of NCLT approval will take another 3 months to complete.

Please see our sector model portfolio (Emkay Alpha Portfolio): [Media & Entertainment \(Page 7\)](#)

### Change in Estimates

EPS Chg FY23E/FY24E (%)	60.9/1.8
Target Price change (%)	-
Target Period (Months)	12
Previous Reco	BUY

### Emkay vs Consensus

	EPS Estimates	
	FY23E	FY24E
Emkay	16.8	74.3
Consensus	37.7	67.3
Mean Consensus TP (12M)	Rs 2,218	

### Stock Details

Bloomberg Code	PVRL IN
Face Value (Rs)	10
Shares outstanding (mn)	61
52 Week H/L	2,215 / 1,224
M Cap (Rs bn/USD bn)	103 / 1.25
Daily Avg Volume (nos.)	1,042,491
Daily Avg Turnover (USD mn)	23.7

### Shareholding Pattern Jun '22

Promoters	17.0%
FIIIs	36.6%
DIIIs	26.2%
Public and Others	20.3%

### Price Performance

(%)	1M	3M	6M	12M
<b>Absolute</b>	(4)	(12)	(11)	(1)
<b>Rel. to Nifty</b>	(3)	(19)	(10)	4

### Relative price trend



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### Naval Seth

naval.seth@emkayglobal.com  
+91 22 6624 2414

#### Pulkit Chawla

pulkit.chawla@emkayglobal.com  
+91 22 6624 2458

### Financial Snapshot (Consolidated)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	2,800	13,310	38,139	49,681	55,304
EBITDA	(3,349)	1,057	12,483	17,633	19,151
EBITDA Margin (%)	(119.6)	7.9	32.7	35.5	34.6
APAT	(7,480)	(4,888)	1,021	4,515	5,423
EPS (Rs)	(123.1)	(80.4)	16.8	74.3	89.3
EPS (% chg)	(2,848.1)	0.0	0.0	342.3	20.1
ROE (%)	(45.1)	(30.5)	7.2	26.6	24.7
P/E (x)	(13.7)	(21.0)	100.5	22.7	18.9
EV/EBITDA (x)	(43.4)	140.7	11.9	8.0	7.2
P/BV (x)	5.6	7.5	7.0	5.3	4.2

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/18/2022 02:20 PM

## Exhibit 1: Actual vs Estimates (Q2FY23)

(Rs mn)	Actual	Estimate		Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Revenue	6,867	6,822	7,850	1%	-13%	
EBITDA	1,537	1,386	1,514	11%	2%	Lower than estimated film exhibition costs and employee costs
EBITDA margin	22.4%	20.3%	19.3%	206 bps	309 bps	
PAT	-712	-804	-498	-11%	43%	

Source: Company, Emkay Research

## Exhibit 2: Summary of quarterly financials

(Rs mn)	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	YoY (%)	QoQ (%)	H1FY23	H1FY22	YoY (%)
<b>Total Revenue</b>	<b>1,203</b>	<b>6,142</b>	<b>5,371</b>	<b>9,814</b>	<b>6,867</b>	<b>471</b>	<b>-30</b>	<b>16,681</b>	<b>1,797</b>	<b>828</b>
Film exhibition cost	263	1182	1322	2389	1462	457	-39	3,852	357	980
as % of sales	21.8	19.2	24.6	24.3	21.3			23.1	19.8	
Cost of materials consumed	138	470	448	765	629	357	-18	1,394	197	607
as % of sales	11.4	7.6	8.3	7.8	9.2			8.4	11.0	
Employee costs	560	788	814	1040	947	69	-9	1,987	1,091	82
as % of sales	46.5	12.8	15.2	10.6	13.8			11.9	60.7	
Repairs & maintenance	925	2054	1788	2204	2292	148	4	4,496	1,743	158
as % of sales	76.9	33.4	33.3	22.5	33.4			27.0	97.0	
<b>Total Expenditure</b>	<b>1,885</b>	<b>4,492</b>	<b>4,373</b>	<b>6,398</b>	<b>5,331</b>	<b>183</b>	<b>-17</b>	<b>11,729</b>	<b>3,388</b>	<b>246</b>
<b>EBITDA</b>	<b>(681)</b>	<b>1,649</b>	<b>999</b>	<b>3,416</b>	<b>1,537</b>	<b>-326</b>	<b>-55</b>	<b>4,952</b>	<b>(1,591)</b>	<b>-411</b>
Depreciation	1,487	1,540	1,687	1,494	1,525	3	2	3,019	2,917	3
EBIT	(2,168)	109	(688)	1,922	11	-101	-99	1,933	(4,508)	-143
Other Income	1,549	956	425	209	164	-89	-21	373	1,881	-80
Interest	1,235	1,257	1,252	1,280	1,277	3	0	2,557	2,472	3
Exceptional item	-	-	-	-	-			0	0	
<b>PBT</b>	<b>(1,855)</b>	<b>(192)</b>	<b>(1,515)</b>	<b>851</b>	<b>(1,102)</b>	<b>-41</b>	<b>-230</b>	<b>(251)</b>	<b>(5,100)</b>	<b>-95</b>
Tax	(322)	(90)	(460)	319	(387)	20	-221	-68	-1,372	-95
<b>PAT before MI</b>	<b>(1,533)</b>	<b>(102)</b>	<b>(1,055)</b>	<b>532</b>	<b>(715)</b>	<b>-53</b>	<b>-234</b>	<b>(183)</b>	<b>(3,728)</b>	<b>-95</b>
Minority interest	(1)	0	-	(2)	(3)	86	18	-5	-3	-
<b>PAT</b>	<b>(1,531)</b>	<b>(102)</b>	<b>(1,055)</b>	<b>534</b>	<b>(712)</b>	<b>-53</b>	<b>-233</b>	<b>(178)</b>	<b>(3,726)</b>	<b>-95</b>
<b>Margins (%)</b>						<b>(bps)</b>	<b>(bps)</b>			<b>(bps)</b>
EBITDA	-56.6	26.9	18.6	34.8	22.4	7,900	-1,243	29.7	-88.5	11,820
EBIT	-180.2	1.8	-12.8	19.6	0.2	18,037	-1,942	11.6	-250.8	26,244
PBT	-154.1	-3.1	-28.2	8.7	-16.0	13,810	-2,472	-1.5	-283.8	28,227
PAT	-127.3	-1.7	-19.6	5.4	-10.4	11,690	-1,581	-1.1	-207.3	20,625
Effective Tax rate	17.4	46.9	30.4	37.5	35.1	1,777	-238	27.1	26.9	16

Source: Company, Emkay Research

## Exhibit 3: Change in estimates

(Rs mn)	FY23E			FY24E			FY25E		
	Old	New	% Change	Old	New	% Change	Old	New	% Change
Revenue	37,752	38,139	1.0	49,721	49,681	-0.1	55,441	55,304	-0.2
EBITDA	12,259	12,483	1.8	17,581	17,633	0.3	19,096	19,151	0.3
EBITDA Margin (%)	32.5	32.7	26 bps	35.4	35.5	13 bps	34.4	34.6	19 bps
EBITDA (Adj. for Ind-AS)	5,766	5,937	3.0	10,515	10,501	-0.1	11,677	11,662	-0.1
PAT	634	1,021	61.0	4,435	4,515	1.8	5,340	5,423	1.6
EPS (Rs)	10.4	16.7	60.9	72.7	74.0	1.8	87.5	88.9	1.6

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/18/2022 02:20 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**Exhibit 4: Pro-forma estimates for merged company (with synergies)**

FY24 (Rs mn)	PVR	Inox	Synergies	Merged Entity	Comments
Ticket	25,879	16,623		42,502	
F&B	15,582	7,906		23,488	
Ad revenue per screen	3.8	2.5			
Number of Screens	1,065	817		1,882	
Ad revenue	3,899	1,974	736	6,609	Discount for Inox will narrow with scale
Convenience Fee	1,740	670	155	2,565	Better negotiations for Inox
Share of sales	3.5%	2.4%			
Others	2,582	784			
<b>Total Revenue</b>	<b>49,681</b>	<b>27,957</b>	<b>891</b>	<b>78,529</b>	
<b>Opex</b>					
Movie exhibition costs	11,193	7,647		18,839	
F&B	4,051	1,897	77	5,872	Vendor consolidation and scale benefits
Employee Costs	4,682	1,380	388		Removing redundancies
Other Expenses	12,122	7,185	388		Scale benefits
<b>Total Expenses</b>	<b>32,048</b>	<b>18,109</b>	<b>853</b>	<b>49,304</b>	
EBITDA	17,633	9,848	1,676	29,225	
<b>EBITDA adj. for Ind-AS</b>	<b>10,501</b>	<b>5,690</b>	<b>1,676</b>	<b>17,867</b>	
Depreciation	7,289	3,439		10,729	
<b>EBIT</b>	<b>10,344</b>	<b>6,408</b>		<b>18,496</b>	
Other Income	280	100		380	
Interest Cost	4,602	2,792		7,394	
<b>PBT</b>	<b>6,022</b>	<b>3,716</b>		<b>11,482</b>	
Tax	1,516	935	422	2,873	
Tax Rate	25.2%	25.2%			
<b>PAT</b>	<b>4,506</b>	<b>2,781</b>	<b>1254</b>	<b>8,609</b>	

Source: Emkay Research

**Exhibit 5: PVR's valuation derived from merged-company financials**

Merged company	Sep-24 TP
<b>Target EV/EBITDA (Sep-24)</b>	<b>12.5</b>
Sep-24 EBITDA - excl IndAS (Rs mn)	18,947
Target EV (Rs mn)	236,840
<b>Target Market Cap (Rs mn)</b>	<b>240,178</b>
Number of Equity Shares (mn)	97
<b>Target Price (Rs/share)</b>	<b>2,466</b>
Weightage	80%
TP - without merger announcement (Rs/share)	1,800
Weightage (Risk to merger)	20%
<b>Final TP (Rs/share)</b>	<b>2,340</b>

Source: Emkay Research

**Key Financials (Consolidated)****Income Statement**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
<b>Revenue</b>	<b>2,800</b>	<b>13,310</b>	<b>38,139</b>	<b>49,681</b>	<b>55,304</b>
<b>Expenditure</b>	<b>6,149</b>	<b>12,253</b>	<b>25,656</b>	<b>32,048</b>	<b>36,153</b>
<b>EBITDA</b>	<b>(3,349)</b>	<b>1,057</b>	<b>12,483</b>	<b>17,633</b>	<b>19,151</b>
Depreciation	5,749	6,144	6,695	7,289	8,052
<b>EBIT</b>	<b>(9,097)</b>	<b>(5,087)</b>	<b>5,788</b>	<b>10,344</b>	<b>11,099</b>
Other Income	4,693	3,261	513	280	339
Interest expenses	4,978	4,982	4,902	4,602	4,205
<b>PBT</b>	<b>(9,382)</b>	<b>(6,807)</b>	<b>1,398</b>	<b>6,022</b>	<b>7,233</b>
Tax	(1,906)	(1,922)	379	1,516	1,821
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	(4)	(3)	2	9	11
<b>Reported Net Income</b>	<b>(7,480)</b>	<b>(4,888)</b>	<b>1,021</b>	<b>4,515</b>	<b>5,423</b>
<b>Adjusted PAT</b>	<b>(7,480)</b>	<b>(4,888)</b>	<b>1,021</b>	<b>4,515</b>	<b>5,423</b>

**Balance Sheet**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	608	610	610	610	610
Reserves & surplus	17,728	13,093	14,114	18,629	24,053
<b>Net worth</b>	<b>18,335</b>	<b>13,703</b>	<b>14,724</b>	<b>19,239</b>	<b>24,663</b>
<b>Minority Interest</b>	<b>0</b>	<b>(3)</b>	<b>(3)</b>	<b>(3)</b>	<b>(3)</b>
<b>Loan Funds</b>	<b>50,031</b>	<b>51,959</b>	<b>49,328</b>	<b>44,701</b>	<b>41,077</b>
Net deferred tax liability	(3,987)	(5,925)	(5,925)	(5,925)	(5,925)
<b>Total Liabilities</b>	<b>64,380</b>	<b>59,734</b>	<b>58,124</b>	<b>58,012</b>	<b>59,812</b>
<b>Net block</b>	<b>54,752</b>	<b>54,073</b>	<b>53,331</b>	<b>52,308</b>	<b>50,607</b>
<b>Investment</b>	<b>12</b>	<b>5</b>	<b>5</b>	<b>5</b>	<b>5</b>
<b>Current Assets</b>	<b>14,098</b>	<b>12,586</b>	<b>11,618</b>	<b>16,637</b>	<b>16,973</b>
Cash & bank balance	7,311	5,798	3,695	5,665	4,846
Other Current Assets	401	476	411	536	596
<b>Current liabilities &amp; Provision</b>	<b>6,654</b>	<b>7,573</b>	<b>7,473</b>	<b>11,583</b>	<b>8,418</b>
<b>Net current assets</b>	<b>7,444</b>	<b>5,013</b>	<b>4,145</b>	<b>5,054</b>	<b>8,555</b>
Misc. exp	0	0	0	0	0
<b>Total Assets</b>	<b>64,380</b>	<b>59,735</b>	<b>58,125</b>	<b>58,012</b>	<b>59,811</b>

**Cash Flow**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
<b>PBT (Ex-Other income) (NI+Dep)</b>	<b>(14,076)</b>	<b>(10,068)</b>	<b>885</b>	<b>5,742</b>	<b>6,894</b>
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(2,305)	(1,021)	(1,234)	1,060	(4,320)
<b>Operating Cashflow</b>	<b>(4,040)</b>	<b>233</b>	<b>6,482</b>	<b>12,865</b>	<b>9,155</b>
Capital expenditure	(2,265)	(3,938)	(5,953)	(6,266)	(6,351)
<b>Free Cash Flow</b>	<b>(6,305)</b>	<b>(3,705)</b>	<b>528</b>	<b>6,598</b>	<b>2,805</b>
Investments	11	7	0	0	0
Other Investing Cash Flow	0	0	0	0	0
<b>Investing Cashflow</b>	<b>2,439</b>	<b>(669)</b>	<b>(5,441)</b>	<b>(5,986)</b>	<b>(6,012)</b>
Equity Capital Raised	94	2	0	0	0
Loans Taken / (Repaid)	(631)	1,928	(2,631)	(4,627)	(3,624)
Dividend paid (incl tax)	0	0	0	0	0
Other Financing Cash Flow	11,204	2,065	4,352	3,927	3,927
<b>Financing Cashflow</b>	<b>5,689</b>	<b>(987)</b>	<b>(3,181)</b>	<b>(5,302)</b>	<b>(3,902)</b>
<b>Net chg in cash</b>	<b>4,089</b>	<b>(1,423)</b>	<b>(2,140)</b>	<b>1,576</b>	<b>(759)</b>
Opening cash position	3,223	7,311	5,798	3,695	5,665
<b>Closing cash position</b>	<b>7,311</b>	<b>5,888</b>	<b>3,658</b>	<b>5,271</b>	<b>4,906</b>

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 10/18/2022 02:20 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**Key Ratios**

<b>Profitability (%)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
EBITDA Margin	(119.6)	7.9	32.7	35.5	34.6
EBIT Margin	(324.9)	(38.2)	15.2	20.8	20.1
Effective Tax Rate	20.3	28.2	27.1	25.2	25.2
Net Margin	(267.0)	(36.7)	2.7	9.1	9.8
ROCE	(6.9)	(2.9)	10.7	18.3	19.4
ROE	(45.1)	(30.5)	7.2	26.6	24.7
RoIC	(12.8)	(6.7)	7.9	14.7	15.7

<b>Per Share Data (Rs)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
EPS	(123.1)	(80.4)	16.8	74.3	89.3
CEPS	(28.5)	20.7	127.0	194.3	221.8
BVPS	301.8	225.5	242.3	316.6	405.9
DPS	0.0	0.0	0.0	0.0	0.0

<b>Valuations (x)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
PER	(13.7)	(21.0)	100.5	22.7	18.9
P/CEPS	(59.2)	81.7	13.3	8.7	7.6
P/BV	5.6	7.5	7.0	5.3	4.2
EV / Sales	51.9	11.2	3.9	2.9	2.5
EV / EBITDA	(43.4)	140.7	11.9	8.0	7.2
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0

<b>Gearing Ratio (x)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
Net Debt/ Equity	2.3	3.4	3.1	2.0	1.5
Net Debt/EBIDTA	(12.8)	43.7	3.7	2.2	1.9
Working Cap Cycle (days)	17.3	(21.5)	4.3	(4.5)	24.5

<b>Growth (%)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
Revenue	(91.8)	375.3	186.5	30.3	11.3
EBITDA	(131.1)	0.0	1,080.5	41.3	8.6
EBIT	(270.3)	0.0	0.0	78.7	7.3
PAT	(2,848.1)	0.0	0.0	342.3	20.1

<b>Quarterly (Rs mn)</b>	<b>Q2FY22</b>	<b>Q3FY22</b>	<b>Q4FY22</b>	<b>Q1FY23</b>	<b>Q2FY23</b>
Revenue	1,203	6,142	5,371	9,814	6,867
EBITDA	(681)	1,649	999	3,416	1,537
<b>EBITDA Margin (%)</b>	<b>(56.6)</b>	<b>26.9</b>	<b>18.6</b>	<b>34.8</b>	<b>22.4</b>
PAT	(1,531)	(102)	(1,055)	534	(712)
<b>EPS (Rs)</b>	<b>(25.2)</b>	<b>(1.7)</b>	<b>(17.4)</b>	<b>8.8</b>	<b>(11.7)</b>

Source: Company, Emkay Research

<b>Shareholding Pattern (%)</b>	<b>Jun-21</b>	<b>Sep-21</b>	<b>Dec-21</b>	<b>Mar-22</b>	<b>Jun-22</b>
Promoters	17.1	17.0	17.0	17.0	17.0
FIs	38.2	37.8	31.9	33.3	36.6
DIs	18.2	26.0	28.3	27.4	26.2
Public and Others	26.6	19.1	22.8	22.2	20.3

Source: Capitaline

## RECOMMENDATION HISTORY (Rs/share)

Date	Closing Price	TP	Period	Rating	Analyst
1-Sep-22	1,855	2,340	12m	Buy	Naval Seth
21-Jul-22	1,915	2,200	12m	Buy	Naval Seth
6-Jul-22	1,874	2,165	12m	Buy	Naval Seth
21-Jun-22	1,782	2,165	12m	Buy	Naval Seth
10-May-22	1,772	2,165	12m	Buy	Naval Seth
28-Mar-22	1,883	2,230	12m	Buy	Naval Seth
23-Jan-22	1,537	1,800	12m	Buy	Naval Seth
23-Oct-21	1,627	1,880	12m	Buy	Naval Seth
2-Jun-21	1,321	1,325	12m	Hold	Naval Seth
21-Feb-21	1,477	1,430	12m	Hold	Naval Seth
16-Jan-21	1,475	1,430	12m	Hold	Naval Seth
4-Nov-20	1,116	1,220	12m	Hold	Naval Seth
15-Sep-20	1,265	1,220	12m	Hold	Naval Seth
10-Jun-20	986	1,017	12m	Hold	Naval Seth
27-Apr-20	947	1,017	12m	Hold	Naval Seth
24-Mar-20	1,343	1,582	12m	Buy	Naval Seth
24-Mar-20	1,343	1,582	12m	Buy	Naval Seth
24-Jan-20	1,924	2,101	12m	Hold	Naval Seth
25-Nov-19	1,758	1,860	12m	Hold	Naval Seth

Source: Company, Emkay Research

## RECOMMENDATION HISTORY (Rs/share)



Source: Bloomberg, Company, Emkay Research

## Emkay Alpha Portfolio – Media & Entertainment



### Analyst: Naval Seth

#### Contact Details

naval.seth@emkayglobal.com  
+91 22 6624 2414

#### Sector

Consumer Durables, Media & Entertainment, SMID and Telecom

#### Analyst bio

Naval holds an MBA in Finance and has more than 14 years of experience in equity research. His team currently covers 19 stocks spread across three different sectors.

### EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	Change vs last published EAP (bps)
<b>Media &amp; Entertainment</b>	<b>0.29</b>	<b>0.29</b>	<b>0%</b>	<b>0</b>	<b>100.00</b>	
Inox Leisure	0.00	0.00	NA	0	0.00	0
PVR	0.00	0.00	NA	0	0.00	0
Sun TV Network	0.04	0.04	0%	0	14.65	0
Zee Entertainment	0.25	0.25	0%	0	85.35	0
<b>Cash</b>	<b>0.00</b>	<b>0.00</b>	<b>NA</b>	<b>0</b>	<b>0.00</b>	<b>0</b>

Source: Emkay Research

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

### Sector portfolio NAV

	Base					Latest
	1-Apr-19	14-Oct-21	13-Apr-22	14-Jul-22	14-Sep-22	14-Oct-22
EAP - Media & Entertainment	100.0	84.2	74.1	59.7	74.3	71.9
BSE200 Neutral Weighted Portfolio (ETF)	100.0	76.0	66.9	53.9	67.1	64.9

\*Performance measurement base date 1<sup>st</sup> April 2019


Source: Emkay Research

### Price Performance (%)

	1m	3m	6m	12m
EAP - Media & Entertainment	-3.3%	20.4%	-3.0%	-14.6%
BSE200 Neutral Weighted Portfolio (ETF)	-3.2%	20.4%	-3.0%	-14.6%

Source: Emkay Research

### NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): [Nifty](#)

Please see our model portfolio (Emkay Alpha Portfolio): [SMID](#)

“Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals”

## Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 18 Oct 2022 01:14:56 (SGT)

Dissemination Date: 18 Oct 2022 01:15:56 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com)

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of October 17, 2022
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report  
**Disclosure of previous investment recommendation produced:**
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of October 17, 2022.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 17, 2022
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment services banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the October 17, 2022

**RESTRICTIONS ON DISTRIBUTION**

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com